DataMeds AI, Inc. — Form S-1/A
Filed October 9, 2026 · analyzed by the Registration Agent
S-1/A
▼ Likely negative
significance 92/100
What the filing says
DataMeds AI (market cap ~$27.1M, 4.5M shares outstanding as of Sept 28, 2026) filed an S-1/A to register 34,462,057 shares for resale by stockholders. These consist of: (1) 1.3M previously issued shares; (2) 21.3M shares from conversion of $21.1M in convertible notes (May 2026) at assumed $1/share; (3) 8.3M shares from warrant exercise at $7.50/share; (4) 3.6M shares from placement agent warrants. At a $1 conversion price, existing shareholders would own only 8.8% post-conversion. Company also acquired Helomics (Sept 11, 2026) for 636,328 shares + $1.36M convertible note at $1/share conversion price.
Why this rating
Extreme dilution event: 34.5M registered shares (764% of current float) would reduce existing shareholders from 100% to <9% ownership if all converted at $1. Helomics acquisition adds further dilution. Company faces Nasdaq compliance pressure and liquidity stress; dilutive capital raises dominate strategy.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
Price action (we called it negative)
before filing · preread $3.02 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.